YU49091B - Sinergistička kombinacija supstance koja sprečava lučenje želudačne kiseline i antibiotika osetljivog na kiseline - Google Patents

Sinergistička kombinacija supstance koja sprečava lučenje želudačne kiseline i antibiotika osetljivog na kiseline

Info

Publication number
YU49091B
YU49091B YU27593A YU27593A YU49091B YU 49091 B YU49091 B YU 49091B YU 27593 A YU27593 A YU 27593A YU 27593 A YU27593 A YU 27593A YU 49091 B YU49091 B YU 49091B
Authority
YU
Yugoslavia
Prior art keywords
acid
combination
substance
synenergetic
gastric acid
Prior art date
Application number
YU27593A
Other languages
English (en)
Other versions
YU27593A (sh
Inventor
Arne Torsten Eek
Sven Erik Sjöstrand
Original Assignee
Aktiebolaget Astra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26661401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU49091(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9201297A external-priority patent/SE9201297D0/xx
Priority claimed from SE9300029A external-priority patent/SE9300029D0/xx
Application filed by Aktiebolaget Astra filed Critical Aktiebolaget Astra
Priority to YU27593A priority Critical patent/YU49091B/sh
Publication of YU27593A publication Critical patent/YU27593A/sh
Publication of YU49091B publication Critical patent/YU49091B/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0469—Suturing instruments for use in minimally invasive surgery, e.g. endoscopic surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
    • A61B17/06066—Needles, e.g. needle tip configurations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/34—Trocars; Puncturing needles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/3006—Properties of materials and coating materials
    • A61F2002/30092—Properties of materials and coating materials using shape memory or superelastic materials, e.g. nitinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0014—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
    • A61F2210/0023—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol operated at different temperatures whilst inside or touching the human body, heated or cooled by external energy source or cold supply
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0014—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
    • A61F2210/0023—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol operated at different temperatures whilst inside or touching the human body, heated or cooled by external energy source or cold supply
    • A61F2210/0047—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol operated at different temperatures whilst inside or touching the human body, heated or cooled by external energy source or cold supply heated by light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Sinergistička kombinacija, naznačena time, što sadrži supstancu sa inhibitornim delovanjem na lučenje želudačne kiseline koja povećava unutarželudačni pH i jednog antibakterijskog jedinjenja osetljivog na kiseline, izuzimajući jedino kombinaciju dve komponente omeprazola i klaritromicina. Prijava sadrži još 3 nezavisna i 17 zavisnih zahteva.
YU27593A 1992-04-24 1993-04-21 Sinergistička kombinacija supstance koja sprečava lučenje želudačne kiseline i antibiotika osetljivog na kiseline YU49091B (sh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
YU27593A YU49091B (sh) 1992-04-24 1993-04-21 Sinergistička kombinacija supstance koja sprečava lučenje želudačne kiseline i antibiotika osetljivog na kiseline

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9201297A SE9201297D0 (sv) 1992-04-24 1992-04-24 Synergistic combination
SE9300029A SE9300029D0 (sv) 1993-01-08 1993-01-08 Synergistic combination ii
YU27593A YU49091B (sh) 1992-04-24 1993-04-21 Sinergistička kombinacija supstance koja sprečava lučenje želudačne kiseline i antibiotika osetljivog na kiseline

Publications (2)

Publication Number Publication Date
YU27593A YU27593A (sh) 1996-10-09
YU49091B true YU49091B (sh) 2003-12-31

Family

ID=26661401

Family Applications (1)

Application Number Title Priority Date Filing Date
YU27593A YU49091B (sh) 1992-04-24 1993-04-21 Sinergistička kombinacija supstance koja sprečava lučenje želudačne kiseline i antibiotika osetljivog na kiseline

Country Status (39)

Country Link
US (3) US5599794A (sh)
EP (2) EP0637241B1 (sh)
JP (1) JPH07505901A (sh)
KR (1) KR100340165B1 (sh)
CN (1) CN1041798C (sh)
AP (1) AP466A (sh)
AT (1) ATE194286T1 (sh)
AU (1) AU669903B2 (sh)
CA (1) CA2133762C (sh)
CZ (1) CZ291201B6 (sh)
DE (2) DE69328967T2 (sh)
DK (1) DK0637241T3 (sh)
DZ (1) DZ1683A1 (sh)
EE (1) EE03149B1 (sh)
ES (1) ES2100135T3 (sh)
FI (1) FI944953A (sh)
GR (2) GR970300011T1 (sh)
HK (1) HK1008296A1 (sh)
HR (1) HRP930755B1 (sh)
HU (1) HUT71225A (sh)
IL (1) IL105155A (sh)
IS (1) IS3990A (sh)
LV (1) LV12625B (sh)
MA (1) MA22878A1 (sh)
MY (1) MY121189A (sh)
NO (1) NO314288B1 (sh)
NZ (1) NZ252759A (sh)
PL (1) PL173485B1 (sh)
PT (1) PT637241E (sh)
RO (1) RO115780B1 (sh)
RU (1) RU2143899C1 (sh)
SG (1) SG52485A1 (sh)
SI (1) SI9300219B (sh)
SK (1) SK282420B6 (sh)
TN (1) TNSN93040A1 (sh)
TW (1) TW276996B (sh)
UA (1) UA43830C2 (sh)
WO (1) WO1993021920A1 (sh)
YU (1) YU49091B (sh)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW420610B (en) * 1994-04-07 2001-02-01 Pfizer A pharmaceutical composition for treating a H. pylori infection or gastric or duodenal ulcers
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
CN1061232C (zh) * 1996-04-12 2001-01-31 马理国 一种治疗胃炎、溃疡的药物组合物
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
DE69827392T2 (de) * 1997-07-25 2005-10-27 Altana Pharma Ag Protonenpumpenhemmer als kombinationstherapeutika mit antibakteriell wirkenden substanzen
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6117868A (en) * 1998-09-16 2000-09-12 Ed. Geistlich Sohne Ag Fur Chemische Industrie Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
AU781133B2 (en) * 1999-02-26 2005-05-05 Nicox S.A. Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US7365047B1 (en) * 1999-09-28 2008-04-29 The Regents Of The University Of California Use of pentagastrin to inhibit gastric acid secretion or as a diuretic
US20020004502A1 (en) * 2000-01-05 2002-01-10 Redmond H. Paul Treatment of inflammatory bowel disease
US6787342B2 (en) 2000-02-16 2004-09-07 Merial Limited Paste formulations
EP1313486A1 (en) * 2000-02-29 2003-05-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
WO2001066117A1 (en) * 2000-03-09 2001-09-13 Ian Andrew Whitcroft Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor
EP1133987A1 (en) * 2000-03-09 2001-09-19 Ian Whitcroft Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor
BR0109544A (pt) * 2000-03-28 2003-06-10 Biochemie Gmbh Partìculas granuladas com sabor ocultado
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
US6544556B1 (en) * 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
SE0103695D0 (sv) 2001-11-07 2001-11-07 Thomas Boren A novel non-antibiotic strategy against OGIP infections based on a cereal product
WO2003063927A2 (en) * 2001-11-16 2003-08-07 Eisai Co. Ltd Compositions and methods to treat gastrointestinal disorders
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
CA2493618A1 (en) * 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
WO2004072061A1 (en) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Method of stabilizing lansoprazole
US20040248942A1 (en) * 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
WO2005007115A2 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060194748A1 (en) * 2005-02-28 2006-08-31 National University Corporation Nagoya University Methods for treating disorders induced by H. pylori infections and pharmaceutical compositions for the same
WO2007070164A1 (en) * 2005-10-19 2007-06-21 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor, a buffering agent and an anti-h. pylori active substance and methods of using same
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10869690B2 (en) * 2017-06-29 2020-12-22 Ethicon Llc Trocar obturator with transverse needle ports
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
JP2694361B2 (ja) * 1989-02-09 1997-12-24 アストラ アクチエボラグ 抗菌剤
EP0382489B1 (en) * 1989-02-10 1994-11-17 Takeda Chemical Industries, Ltd. Use of benzimidazole derivatives as antibacterial agents
GB9018603D0 (en) * 1990-08-24 1990-10-10 Smith Kline French Lab Compositions
EP0548103B1 (de) * 1990-09-14 2001-12-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Verwendung von pyridylmethylsulfinyl-1h-benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen

Also Published As

Publication number Publication date
TW276996B (sh) 1996-06-01
HK1008296A1 (en) 1999-05-07
SK282420B6 (sk) 2002-01-07
AU4273793A (en) 1993-11-29
CZ259394A3 (en) 1995-08-16
NO944010D0 (no) 1994-10-21
SK127594A3 (en) 1995-04-12
FI944953A0 (fi) 1994-10-21
LV12625B (en) 2001-07-20
CN1041798C (zh) 1999-01-27
GR3034470T3 (en) 2000-12-29
DE69328967D1 (de) 2000-08-10
EP0637241B1 (en) 2000-07-05
JPH07505901A (ja) 1995-06-29
IL105155A0 (en) 1993-07-08
RO115780B1 (ro) 2000-06-30
SI9300219A (sl) 1993-12-31
DE69328967T2 (de) 2000-12-07
HUT71225A (en) 1995-11-28
US5629305A (en) 1997-05-13
MY121189A (en) 2006-01-28
DK0637241T3 (da) 2000-09-11
IL105155A (en) 1999-05-09
RU2143899C1 (ru) 2000-01-10
NO944010L (no) 1994-10-21
PT637241E (pt) 2000-10-31
NO314288B1 (no) 2003-03-03
AP9300518A0 (en) 1993-04-30
TNSN93040A1 (fr) 1994-03-17
EE03149B1 (et) 1999-02-15
ES2100135T3 (es) 2000-11-16
EP0956857A3 (en) 2003-11-26
AP466A (en) 1996-03-05
DZ1683A1 (fr) 2002-02-17
US5599794A (en) 1997-02-04
HRP930755A2 (en) 1994-10-31
DE637241T1 (de) 1997-09-11
NZ252759A (en) 1996-12-20
YU27593A (sh) 1996-10-09
KR100340165B1 (ko) 2002-10-04
HU9403069D0 (en) 1994-12-28
CA2133762A1 (en) 1993-11-11
GR970300011T1 (en) 1997-05-31
CN1081614A (zh) 1994-02-09
LV12625A (en) 2001-03-20
MA22878A1 (fr) 1993-12-31
UA43830C2 (uk) 2002-01-15
US5633244A (en) 1997-05-27
PL173485B1 (pl) 1998-03-31
CZ291201B6 (cs) 2003-01-15
IS3990A (is) 1993-10-25
ES2100135T1 (es) 1997-06-16
SG52485A1 (en) 1998-09-28
SI9300219B (en) 2001-12-31
AU669903B2 (en) 1996-06-27
FI944953A (fi) 1994-10-21
HRP930755B1 (en) 2001-04-30
WO1993021920A1 (en) 1993-11-11
EP0637241A1 (en) 1995-02-08
EP0956857A2 (en) 1999-11-17
CA2133762C (en) 2000-08-01
ATE194286T1 (de) 2000-07-15

Similar Documents

Publication Publication Date Title
YU49091B (sh) Sinergistička kombinacija supstance koja sprečava lučenje želudačne kiseline i antibiotika osetljivog na kiseline
NO882123D0 (no) Maskering for antibiotikum.
DE69131520D1 (de) Feldeffekttransistor mit geneigtem Kanal
NL300035I2 (nl) Gesubstitueerde thiazolidinedionderivaten.
ATE75936T1 (de) Zusammensetzungen mit verzoegerten wirkstoffabgaben.
DE69416182D1 (de) Übertragungsbandkassette, Umschliessungsgehäuse dafür und Übertragungsvorrichtung von Beschichtungsfilmen damit versehen
FI891438A0 (fi) Foerfarande foer framstaellning av farmaceutiska sammansaettningar som inverkar i synnerhet pao det kardiovaskulaera systemet.
DE59207033D1 (de) Balhimycin-abgeleitete glykopeptidische Antibiotika
GB2257830B (en) Low output-capacity, double-diffused field effect transistor
FI920853A0 (fi) Anordning foer fjaerrtestning av ledningar.
DE69200787D1 (de) Videoverstärkervorrichtung.
NZ513603A (en) ADP-ribosylation inhibitors and remedies for endotoxic bacterial enteric infection containing proanthocyanidin as the active ingredient
ES1020342Y (es) Enfriador evaporativo indirecto perfeccionado.
ES1018275Y (es) Valvula de compuerta perfeccionada.
ES1020962Y (es) Valvula de compuerta perfeccionada.
FI912954A0 (fi) Anordning foer byte av klocksignal.
KR940001985U (ko) 슬릿밸브(Slit valve)
IT232298Y1 (it) Monocomando di rubinetto perfezionato.
BG96869A (bg) Приложение на васillus тнuringiеnsis активен спрямо твърдокрили насекоми (разред соlеортеrа) за контрол на житния листен бръмбър оulема меlаnора (l.) lema melanopa (l))
FI922305A0 (fi) Knappsats foer inmatning av en kod som skall hemlighaollas.
NO911212L (no) Innretning for oppdretting av svin.
MX200843B (es) Compuesto absorbente.
ES1012936Y (es) Valvula de compuerta perfeccionada.
ES1019663Y (es) Frigorifico perfeccionado.
ES1021242Y (es) Aparato humificador perfeccionado.